Introduction
============

The incidence of nonmelanoma skin cancer (NMSC), which includes squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), has exhibited a marked increase in the previous decade and at present is the most common malignancy in Caucasian populations ([@b1-etm-0-0-7261]). NMSC is associated with a low rate of mortality but a high rate of disfigurement in cases where skin lesions are located on the head and neck. In addition, SCC occurs less frequently compared with BCC but is generally more aggressive. Sunlight ([@b2-etm-0-0-7261]), viral infection ([@b3-etm-0-0-7261]), diet ([@b4-etm-0-0-7261]), immunosuppression in organ transplant recipients ([@b5-etm-0-0-7261]) and induction of spontaneous genetic mutations ([@b6-etm-0-0-7261]) have been regarded as causes for NMSC. Tumors are markedly associated with chronic ultraviolet (UV) radiation exposure and occur primarily on sun-exposed areas of the body ([@b7-etm-0-0-7261]). Early detection and surgical removal may prevent the majority of complications. However, skin cancer has a high rate of recurrence and occasionally tumors progress to advanced stages that are difficult to treat with present therapeutic modalities; additionally, advanced-stage tumors become associated with high morbidity and decreased survival rates ([@b8-etm-0-0-7261]). At present, treatment options have remained limited for locally advanced or metastatic NMSC. Therefore, an in-depth understanding of the molecular basis of skin tumorigenesis is necessary in order to develop novel and specific diagnostic biomarkers and efficient therapies.

Src homology 3 and multiple ankyrin repeat domains protein (SHANK)-associated RH domain-interacting protein (SHARPIN) is a 387-amino acid protein that was originally identified as a SHANK-binding protein, which is enriched in the postsynaptic density of excitatory neurotransmitters ([@b9-etm-0-0-7261]). In addition, SHARPIN has been detected in cancer in the brain, spleen, lungs and other organs. Seymour *et al* ([@b10-etm-0-0-7261]) have identified *SHARPIN* as a gene mutated in chronic proliferative dermatitis (*cpdm*) mice (*Sharpin*cpdm/cpdm) which spontaneously causes chronic inflammation, primarily in the skin, but also in other tissues including the gut, lung, liver and esophagus. SHARPIN has been previously identified as a common component of the linear ubiquitin chain assembly complex (LUBAC) which also contains E3 ubiquitin protein ligase ring finger protein 31 and RanBP-type and C3HC4-type zinc finger-containing protein 1 (HOIL-1L) ([@b11-etm-0-0-7261]). The C-terminal portion of SHARPIN consists of a ubiquitin-like (UBL) domain followed by an Npl4-zinc finger (NZF) domain and is important for the formation of a complex with the LUBAC component, haem-oxidized iron-regulatory protein 2 ubiquitin ligase-1 interacting protein and ubiquitin ([@b9-etm-0-0-7261]). LUBAC is an important component of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway, which is a critical regulator of inflammation, immune response and lymphoid tissue development ([@b12-etm-0-0-7261]). NF-κB signaling is generally classified into canonical and non-canonical pathways. The canonical pathway, primarily triggered by tumor necrosis factor (TNF), lipopolysaccharides, and T and B cell receptors, occurs in the majority of cells as the principal NF-κB pathway. Upon stimulation, the downstream kinase inhibitor of κB (IκB) kinase (IKK) complex, composed of two catalytic subunits (IKKα and IKKβ) and one regulatory subunit \[NF-κB essential modulator (NEMO)\], is activated, allowing the phosphorylation of the IκBα inhibitory protein. A linear form of polyubiquitin chains was previously identified in the NF-κB signaling pathway following TNF stimulation ([@b13-etm-0-0-7261]). The generation of linear ubiquitin polymers is catalyzed by LUBAC. Previous evidence indicates that LUBAC is recruited to TNF receptor complexes upon TNF induction, and then conjugates linear ubiquitin chains to the regulatory subunit NEMO of the IKK complex ([@b14-etm-0-0-7261]). This activates the kinase activity of IKK and ubiquitin-dependent degradation of phosphorylated IκBα, therefore enabling the nuclear translocation of NF-κB dimers and downstream gene expression ([@b15-etm-0-0-7261]). SHARPIN contains a PH (pleckstrin homology) domain at the N-terminus, which serves as a dimerization domain and may serve a role in other physiological functions of SHARPIN, including its tumor-associated role and its ability to inhibit β1-integrin activation ([@b16-etm-0-0-7261]). Furthermore, SHARPIN has been identified as a commonly overexpressed proto-oncogene and functionally serves tumor-associated roles during cancer progression according to previous studies ([@b17-etm-0-0-7261]--[@b23-etm-0-0-7261]). However, data regarding the function of SHARPIN in the pathogenesis and development of NMSC is lacking. These background data prompted the present study to investigate the expression and mutations of SHARPIN in skin tumors and identify a promising prognostic biomarker and therapeutic target for NMSC. Immunohistochemistry was utilized in the current study to assess SHARPIN expression in NMSCs and polymerase chain reaction (PCR) was used to detect mutations of *SHARPIN* in NMSCs. It was revealed that the expression of SHARPIN was absent in cancer nests and was significantly low in precancerous NMSC lesions. The total mutation frequency of SHARPIN was 21.8% in BCC and 17.0% in SCC.

Materials and methods
=====================

### Literature retrieval

To acquire all literature regarding SHARPIN and NMSCs, PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>) was searched using the following search string to identify relevant papers: (NMSC) OR non-melanoma skin cancer AND SHARPIN. No restrictions on publication date or language were imposed during the search strategy. No articles were identified.

### Specimen selection

Anonymized control DNA samples from blood specimens of 100 normal individuals and skin tissues from 12 healthy volunteers who received cosmetic surgeries were obtained according to a protocol approved by the Southern Medical University Shenzhen Hospital Subject Review Board. All 100 normal individuals and 12 healthy volunteers did not have skin diseases. Formalin-fixed paraffin-embedded (FFPE) samples were retrieved from the Department of Dermatology of Shenzhen Hospital in Southern Medical University (Shenzhen, China). All samples from January 2012 to June 2017 were biopsied. All samples were fixed for 24 h in 10% formalin solution at room temperature. The thickness of the sections was 4 µm. A total of 85 BCC, 77 SCC and 21 keratoacanthoma (KA) FFPE samples were collected. The diagnoses of the samples were confirmed by pathologists from the Department of Dermatology of Shenzhen Hospital in Southern Medical University. Informed consent was obtained from all patients.

### DNA extraction and mutation sequencing

DNA was extracted from the blood using the phenol-chloroform method ([@b24-etm-0-0-7261]). The FFPE genomic DNA was extracted using a QIAamp DNA FFPE Tissue kit (Qiagen GmbH, Hilden, Germany). To detect hotspot mutations, 8 exons and exon-intron adjacent sequences of the SHARPIN gene were amplified using PCR. In the DNA from the tumor samples, each amplification reaction was performed under standard conditions in a 20 µl PCR mixture containing 70--150 ng template DNA, 10 pmol primers, and 10 µl 2X Taq Master Mix (Dye Plus) (Vazyme, Piscataway, NJ, USA). The GC percentage of Exon 1 was relatively high; therefore, the 2X Taq Master Mix (Dye Plus) was replaced by 2X Phanta Max Master Mix (Vazyme) in the amplification of Exon 1. The 8 primer pairs that were used are listed in [Table I](#tI-etm-0-0-7261){ref-type="table"}. Exon 3 was amplified by PCR. The thermocycler conditions for the standard and nested PCR protocols are listed in [Table II](#tII-etm-0-0-7261){ref-type="table"}. PCR products were purified using QIAquick reagent (Qiagen GmbH) and directly sequenced based on the Big Dye Terminator sequencing chemistry (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA USA) in an ABI3130 automated sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.). All mutations were confirmed through repeated bidirectional sequencing on the ABI sequencer. Gene sequences were blasted using DNASTAR Lasergene 7.1 (DNASTAR Inc., Madison, WI, USA).

### Immunohistochemistry

FFPE sections were deparaffinized in xylene at room temperature and rehydrated in 100, 95, 90, 80 and 70% alcohol solutions prepared with absolute ethyl alcohol and distilled water. For antigen retrieval, sections were heated in citrate buffer (pH 6.0) for 15 min at 100°C in a microwave oven and naturally cooled to room temperature. Subsequently, the samples were blocked with a mixture of methanol and 0.75% hydrogen peroxide for 20 min at room temperature. Following washing with PBS, samples were incubated with SHARPIN antibody (cat. no., sc-98127; Santa Cruz Biotechnology, Inc., Dallas, TX, USA; dilution, 1:100) at 4°C overnight. Subsequent to incubation, slides were washed three times with PBS. The slides were then processed using a 2-step Plus^®^ Poly-horseradish peroxidase Anti-Mouse/Rabbit IgG Detection System (cat. no., PV-9000; ZSGB-BIO; OriGene Technologies, Inc., Beijing, China) and were developed with a DAB Detection kit (Enhanced Polymer; cat. no., PV-9000-D; ZSGB-BIO; OriGene Technologies, Inc.) for 3 min at room temperature. SHARPIN immunohistochemical staining was expected to be localized to the cytoplasm.

### Histologic scoring and analysis

Samples were evaluated using a standard light microscopic technique (magnification, ×200) as performed by two pathologists (Shenzhen Hospital in Southern Medical University). Staining for the SHARPIN protein was evaluated in the tumors and in the normal skin tissues, which were invariably SHARPIN-positive and served as positive controls. Each tumor sample was scored by the cross-product (H score) of the percentage of tumor cell staining at each of the 3 staining intensities. Degrees of staining were divided into four levels: None, 0; weak, 1; moderate, 2; and strong, 3. For example, a particular tumor may have 30% cell staining at intensity =1 and 70% of cell staining at intensity =3, for a combined H score of 240 \[(30×1) + (70×3) =240\] out of a maximum of 300. This system was performed as described previously by Bollag *et al* ([@b25-etm-0-0-7261]). Concordance was observed between the scores given by the two pathologists (81% of the scores were in agreement within a 40-point range). Cases with discrepancies of \<50 points were recorded and reconciled on a two-headed microscope. Final H scores for each case were averaged by each pathologist. The expression scale of SHARPIN was graded by H score as follows: Low, H score 1--100; moderate, H score 101--200; and high, H score 201--300.

### Statistical analysis

Statistical analysis was performed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). Data were presented as the mean ± standard deviation. Differences in SHARPIN expression levels between normal skin and SCC, BCC and KA samples were analyzed using one-way analysis of variance and Tamhane\'s T2 post hoc test. The Broder grading system of SCC is commonly utilized to assess prognosis. It divides SCC into four categories based on histological grade. Grade I is composed of well-differentiated tumors, in which 75--100% of squamous cells are differentiated. Grade II is composed of moderately differentiated tumors in which 50--75% of squamous cells are differentiated. Grade III is composed of poorly differentiated tumors in which only 25--50% of cells are differentiated. Grade IV is an anaplastic tumor in which 0--25% of cells are differentiated ([@b26-etm-0-0-7261]). Main histologic variants of BCC include nodular type, adenoidal type, superficial type and sclerosing type ([@b27-etm-0-0-7261]). Associations between SHARPIN expression levels and aforementioned clinicopathological parameters were analyzed using the χ2 test for categorical variables. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### SHARPIN is aberrantly decreased in human NMSC

The SHARPIN protein was absent in the tumor nests and significantly decreased in precancerous lesions of SCC and BCC ([Fig. 1](#f1-etm-0-0-7261){ref-type="fig"}) when compared to normal epithelium ([Fig. 2](#f2-etm-0-0-7261){ref-type="fig"}). In addition, SHARPIN was moderately to highly expressed in KA samples ([Fig. 3](#f3-etm-0-0-7261){ref-type="fig"}).

In BCC, SHARPIN expression was low in 63 cases (74.5%) and moderate in 22 cases (25.5%). In SCC, SHARPIN expression was low in 52 cases (68.1%) and moderate in 25 cases (31.9%). Furthermore, the difference in SHARPIN expression levels between BCC and normal skin, SCC and normal skin, and SCC and KA were all significant (P\<0.05) ([Fig. 4](#f4-etm-0-0-7261){ref-type="fig"}). However, no significant association was observed between SHARPIN expression and tumor grading of SCC. Demographics of all the patients and their H scores are summarized in [Tables III](#tIII-etm-0-0-7261){ref-type="table"}--[VI](#tVI-etm-0-0-7261){ref-type="table"}.

### SHARPIN mutation analysis

A total of 8 exons and exon-intron adjacent sequences of SHARPIN were analyzed using DNA extracts from FFPE blocks of BCC, SCC and KA samples and healthy skin specimens, and DNA extracts from peripheral blood samples of 100 normal controls. Complete descriptions of the mutations detected in BCC and SCC are presented in [Table VII](#tVII-etm-0-0-7261){ref-type="table"}. Total mutation rates were 21.8% in BCC and 17.0% in SCC samples. The C\>T substitutions were 5.5% in BCC and 6.4% in SCC. Additionally, no mutations of SHARPIN were detected in DNA extracts from one benign skin tumor, 12 healthy skin tissues and blood samples from 100 normal individuals.

Discussion
==========

The present study evaluated the expression of SHARPIN protein and analyzed the sequences of *SHARPIN* in NMSC. To the best of our knowledge, this is the first study to comprehensively investigate the expression and mutations of SHARPIN in a large series of patients with NMSC.

The essential contribution of SHARPIN to the activation of NF-κB supports the possibility that SHARPIN promotes tumorigenesis, as NF-κB signaling possesses well-demonstrated tumorigenic properties ([@b12-etm-0-0-7261]). This is supported by the SHARPIN-mediated suppression of apoptosis in the keratinocytes and hepatocytes of *cpdm* mice ([@b18-etm-0-0-7261]). Additionally, SHARPIN promotes the migration of Chinese hamster ovary cells *in vitro* and lymphocytes *in vivo*, and increases the lung metastasis of osteosarcoma *in vivo* in immunocompromised mice ([@b19-etm-0-0-7261]). In addition, the upregulation of *SHARPIN* has been observed in different types of internal solid cancer, including ovarian cancer, renal cell carcinoma, and cervical and prostate cancer ([@b20-etm-0-0-7261],[@b21-etm-0-0-7261]). Furthermore, SHARPIN induces PTEN polyubiquitination independently of the K48 linkage. This process requires the UBL domain, which mediates SHARPIN\'s association with PTEN and its ability to bind ubiquitin via the NZF motif ([@b28-etm-0-0-7261]). Rantala *et al* ([@b16-etm-0-0-7261]) demonstrated that SHARPIN inactivates integrins in a number of different cell types and affects integrin-dependent cellular functions. Bii *et al* ([@b22-etm-0-0-7261]) identified SHARPIN as a metastasis gene in breast cancer using a replication-incompetent gammaretroviral vector, suggesting the potential of SHARPIN as a biomarker for stratifying patients with breast cancer. Additionally, Haris *et al* ([@b23-etm-0-0-7261]) identified that SHARPIN was significantly upregulated in U87 glioblastoma cells upon treatment with Aloe-emodin. Collectively, substantial evidence has demonstrated the role of SHARPIN in promoting tumorigenesis. Despite these data, a PubMed search did not identify any studies examining the expression of SHARPIN in NMSC. Therefore, the present study explored the expression of *SHARPIN* in three types of skin tumors, including the malignant forms BCC and SCC.

Firstly, the expression of SHARPIN was detected via immunohistochemistry. Contrary to the results of examination of internal solid tumors ([@b17-etm-0-0-7261]), SHARPIN expression was downregulated or absent in the majority of NMSC samples compared with normal skin tissues and KA. KA is commonly diagnosed clinically as it rapidly appears and develops as a raised lesion; however, as a non-pigmented lesion with a central keratin plug, SCC may also exhibit the same appearance. Furthermore, cases of KA with SCC arising from the base have been identified ([@b29-etm-0-0-7261]). Differential diagnosis between KA and SCC is challenging due to their similarities and the lack of reliable diagnostic criteria to distinguish them. Therefore, whether KA is a separate benign entity, or a variant of SCC, is controversial. At present, no biomarkers exist to distinguish SCC from KA, and KA lesions are commonly treated in the same way as SCC. However, SCC has a poorer prognosis than KA and is treated more aggressively; therefore, distinguishing between these two malignancies would be advantageous in order to implement the appropriate treatment, thereby decreasing unnecessary surgeries, the burden on the healthcare system and, importantly, the anxiety of the patients ([@b30-etm-0-0-7261]). Based on the results of the present study, that SHARPIN is absent or exhibits low expression in SCC but a high expression in KA, we hypothesize that SHARPIN may allow early differentiation and *in situ* treatment of SCC and KA to avoid metastasis and tissue destruction of SCC and the overtreatment of KA.

At present, the mechanism of how the downregulation of SHARPIN promotes skin tumorigenesis remains to be elucidated. Ikeda *et al* ([@b11-etm-0-0-7261]) identified that the absence of *SHARPIN* in *cpdm* mice caused dysregulation of NF-κB and increased apoptosis and necrosis of mouse embryonic fibroblasts. The data from the present study suggested that the downregulation of SHARPIN in NMSC may impair the function of LUBAC, and subsequently, the activation of NF-κB. In the majority of tumors, the aberrant activation of NF-κB signaling stimulates tumor cell proliferation, invasion and metastasis ([@b31-etm-0-0-7261]). Counterintuitively, Hogerlinden *et al* ([@b32-etm-0-0-7261]) demonstrated that selective inhibition of Rel/NF-κB signaling in the skin leads to disturbed epidermal homeostasis and hair follicle development, increased frequency of apoptotic keratinocytes and spontaneous development of SCC. Notably, a number of data have challenged the view that apoptotic signaling solely serves to inhibit cancer, arguing instead that apoptosis is responsible for various effects that may be tumor-promoting ([@b33-etm-0-0-7261]--[@b36-etm-0-0-7261]). Apoptotic cell death is a cell-autonomous event, but its effects are not; dying cells affect their surrounding environments in various ways, which may include stimulating the proliferation of neighboring cells, affecting intra-tumoral cell competition and exerting paracrine effects on tumor microenvironments. Various data support the hypothesis that apoptosis may promote tumorigenesis through the recruitment and activation of phagocytic macrophages at the tumor sites ([@b37-etm-0-0-7261]). Taken together, we hypothesized that decreased SHARPIN expression may promote NMSC through the impaired activation of NF-κB and increased apoptosis and necrosis of epidermal cells, which may disrupt the homeostasis of the epidermis and lead to tumorigenesis.

Traditional Sanger sequencing has been the gold standard for identifying mutations for a number of years due to its low false-positive rate and high specificity ([@b21-etm-0-0-7261]). Therefore, in the present study, DNA was extracted from NMSC FFPE blocks and mutations in the exons of *SHARPIN* were detected. The results indicated that high proportions of BCC and SCC contained mutations of the *SHARPIN* gene. Mutations in *SHARPIN* exons were identified in 21.8% of BCC and 17.0% of SCC in the present study. The proportions of C\>T substitutions were 5.5% in BCC and 6.4% in SCC samples, which were identified as characteristic of mutations associated with exposure to UV exposure ([@b38-etm-0-0-7261]). In addition, the mutations were not only located in the UBL domain of SHARPIN but also in the PH and NZF domains, thereby potentially affecting other functions of SHARPIN besides the formation of LUBAC. Furthermore, SHARPIN has been indicated to inactivate integrins in a number of cell types and affect integrin-dependent cellular functions independent of LUBAC ([@b16-etm-0-0-7261]). Approximately one-half of the cellular SHARPIN is not associated with the LUBAC complex ([@b28-etm-0-0-7261]). Therefore, the present study concluded that SHARPIN is a multifunctional molecule and may promote the pathogenesis of NMSC through different mechanisms.

Overall, the present study contributes to a growing body of evidence supporting the importance of *SHARPIN* in NMSC. The results suggest an association between NMSC and low to absent SHARPIN expression and SHARPIN mutations.

It was identified that SHARPIN protein expression was absent in cancer nests and significantly decreased in precancerous lesions of SCC and BCC, but was high in normal skin or in KA. The total mutation rates of *SHARPIN* were 21.8% in BCC and 17.0% in SCC. These data indicated that SHARPIN may serve a tumor-suppressing role and act as a promising diagnostic biomarker in NMSC.
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![Expression of SHARPIN in nonmelanoma skin cancer. (A) The expression of SHARPIN in BCC at magnification, ×100. The red arrow indicates BCC cells. The black arrow indicates sebaceous glands. (B) The expression of SHARPIN in SCC at magnification, ×100. The red arrow indicates SCC cells. The black arrow indicates epithelia. SHARPIN, Src homology 3 and multiple ankyrin repeat domains protein-associated RH domain-interacting protein; BCC, basal cell carcinoma; SCC, squamous cell carcinoma.](etm-17-04-2746-g00){#f1-etm-0-0-7261}

![Expression of Src homology 3 and multiple ankyrin repeat domains protein-associated RH domain-interacting protein in normal skin at magnification, ×100. The black arrow indicates the epithelia in normal skin.](etm-17-04-2746-g01){#f2-etm-0-0-7261}

![Expression of Src homology 3 and multiple ankyrin repeat domains protein-associated RH domain-interacting protein in KA at magnification, ×200. The red arrow indicates tumors cells in KA. KA, keratoacanthoma.](etm-17-04-2746-g02){#f3-etm-0-0-7261}

![H scores of BCC, SCC, KA and normal skin. Values are mean ± standard deviation. \*P\<0.05 using one-way analysis of variance and Tamhane\'s T2 post hoc test. BCC, basal cell carcinoma; SCC, squamous cell carcinoma; KA, keratoacanthoma.](etm-17-04-2746-g03){#f4-etm-0-0-7261}

###### 

Primers used in the screening of Src homology 3 and multiple ankyrin repeat domains protein-associated RH domain-interacting protein gene mutations.

  Exon   Forward primer (5′-3′)   Reverse primer (5′-3′)
  ------ ------------------------ ------------------------
  1      CAGGTTCGCGGCCCGTGTTT     AAGAGGACTGACCGCGCGCC
  2      ATTTCTTTGCTCCTCGTGCG     CTTCCCAGACATCCAGCAGT
  3      CAGCACAGCACACCCATATC     GGGACTATCTGCTATCCCCG
  4      AGCAGATAGTCCCCAGTGGT     GTGGGTTCAGGGATGGATGG
  5      CATCAGGTGAGGCCTGGG       CCGAGCTCTGAGAACACCTG
  6      ATCACCTGCCCTGATGCTC      GTGGAGCTCAGGACTGTGG
  7      CACAGTCCTGAGCTCCACC      GTTGCTTCCCTGCTCTTTCC
  8      CAGGGAAGCAACAACTGTCT     ATTCCTGTGGATTCTGCCCT

###### 

PCR amplification thermocycler conditions of Src homology 3 and multiple ankyrin repeat domains protein-associated RH domain-interacting protein gene.

          Touchdown PCR    Ordinary PCR                         
  ------- ---------------- -------------- ---- ---------------- -----------
      1   94               5 min          1    94               5 min
      2   94               30 sec         2    94               30 sec
      3   63, EXa −0.5     30 sec         3    60/56/57b        30 sec
      4   72               20 sec         4    72               20 sec
      5   Back to step 2   16 times       5    Back to step 2   35 times
      6   94               30 sec         6    72               7 min
      7   54               30 sec         7      4              Until use
      8   72               20 sec         --   --               --
      9   Back to step 5   20 times       --   --               --
  10      72               7 min          --   --               --
  11        4              Until use      --   --               --

PCR, polymerase chain reaction; E, exon. E3 was amplified by Touchdown PCR. E1, E2, E4, E5, E6, E7 and E8 were amplified by ordinary PCR. aEX indicates that the annealing temperature decreased by 0.5°C per cycle. bAnnealing temperature of E1 was 60°C, annealing temperature of E2, E4, E5, and E8 was 56°C and annealing temperature of E6 and E7 was 57°C.

###### 

Demographics and H scores of patients with basal cell carcinoma.

  ID    Sex   Age, y   Location         Type               H score
  ----- ----- -------- ---------------- ------------------ ---------
  B01   M     74       Nose             adenoidal type     10
  B02   F     52       Right ear        adenoidal type     10
  B03   M     72       Trunk            superficial type   10
  B04   F     70       Right hand       superficial type   10
  B05   M     68       Right shoulder   superficial type   10
  B06   M     62       Upper lip        nodular type       10
  B07   M     63       Nose             adenoidal type     10
  B08   M     44       Lower lip        sclerosing type    10
  B09   F     82       Lower lip        sclerosing type    10
  B10   F     45       Head             adenoidal type     10
  B11   F     70       Nose             adenoidal type     15
  B12   F     63       Right hip        adenoidal type     20
  B13   F     49       Right thigh      sclerosing type    20
  B14   F     73       Left forearm     superficial type   20
  B15   M     69       Upper lip        nodular type       20
  B16   M     69       Nose             adenoidal type     20
  B17   M     65       Left hand        sclerosing type    20
  B18   M     67       Nose             adenoidal type     20
  B19   F     47       Nose             adenoidal type     20
  B20   M     65       Neck             superficial type   20
  B21   F     73       Head             nodular type       25
  B22   M     22       Nose             nodular type       30
  B23   M     58       Lower lip        adenoidal type     30
  B24   F     58       Nose             superficial type   30
  B25   F     57       Left cheek       adenoidal type     35
  B26   M     59       Upper lip        adenoidal type     35
  B27   F     68       Right tempus     superficial type   40
  B28   F     80       Upper lip        pigmented type     40
  B29   F     95       Back             nodular type       40
  B30   M     78       Back             nodular type       40
  B31   F     65       Left tempus      nodular type       40
  B32   F     76       Back             pigmented type     40
  B33   M     64       Left leg         superficial type   40
  B34   M     43       Head             sclerosing type    45
  B35   F     41       Left forehead    pigmented type     50
  B36   F     68       Chest            pigmented type     50
  B37   F     83       Right hand       nodular type       50
  B38   M     89       Nose             superficial type   50
  B39   F     75       Left hand        pigmented type     50
  B40   F     75       Lower lip        superficial type   55
  B41   M     63       Nose             sclerosing type    55
  B42   M     45       Upper lip        nodular type       60
  B43   F     64       Left thigh       adenoidal type     60
  B44   M     50       Back             nodular type       60
  B45   M     59       Lower lip        nodular type       60
  B46   M     46       Upper lip        adenoidal type     70
  B47   M     81       Head             nodular type       70
  B48   F     60       Lower lip        nodular type       70
  B49   M     58       Left thigh       adenoidal type     70
  B50   F     43       Anus             nodular type       70
  B51   F     78       Left thigh       nodular type       75
  B52   F     61       Nose             nodular type       80
  B53   M     56       Nose             nodular type       80
  B54   M     53       Left thigh       nodular type       80
  B55   F     45       Right cheek      pigmented type     80
  B56   F     29       Left check       superficial type   80
  B57   F     44       Left thigh       adenoidal type     80
  B58   F     58       Left thigh       nodular type       80
  B59   F     73       Back             nodular type       85
  B60   M     58       Nose             superficial type   90
  B61   F     73       Head             nodular type       90
  B62   M     73       Left cheek       sclerosing type    90
  B63   F     57       Nose             nodular type       90
  B64   F     34       Lower lip        superficial type   100
  B65   F     41       Nose             nodular type       100
  B66   F     34       Lower lip        superficial type   100
  B67   M     73       Lower lip        nodular type       100
  B68   M     82       Nose             nodular type       100
  B69   M     63       Back             nodular type       100
  B70   F     38       Upper lip        superficial type   105
  B71   F     53       Right tempus     nodular type       105
  B72   F     64       Back             nodular type       110
  B73   F     53       Lower lip        nodular type       120
  B74   F     63       Back             nodular type       120
  B75   M     35       Upper lip        superficial type   120
  B76   F     44       Nose             superficial type   130
  B77   F     60       Right tempus     nodular type       135
  B78   F     70       Nose             superficial type   140
  B79   M     37       Nose             nodular type       140
  B80   F     36       Nose             nodular type       140
  B81   F     64       Right tempus     adenoidal type     150
  B82   M     56       Lower lip        sclerosing type    150
  B83   M     73       Back             superficial type   160
  B84   F     47       Right hand       nodular type       160
  B85   M     58       Lower lip        nodular type       190

F, female; M, male.

###### 

Demographics and H scores of patients with squamous cell carcinoma.

  ID    Sex   Age, y   Location        Broder grading system   H score
  ----- ----- -------- --------------- ----------------------- ---------
  S01   M     57       Left tempus     I                       3
  S02   M     56       Right tempus    I                       5
  S03   F     43       Right cheek     I                       10
  S04   M     28       Nose            II                      10
  S05   F     78       Perioral        II                      10
  S06   M     72       Left tempus     I                       10
  S07   M     79       Left thigh      II                      20
  S08   F     78       Upper lip       I                       20
  S09   M     88       Lower lip       I                       20
  S10   M     52       Nose            I                       20
  S11   F     59       Trunk           II                      20
  S12   M     68       Right eyebrow   III--IV                 20
  S13   M     48       Left eyelid     III                     25
  S14   M     72       Left forehead   II                      25
  S15   F     42       Right forearm   II                      25
  S16   M     65       Right cheek     I                       30
  S17   F     76       Anus            II                      30
  S18   F     30       Left cheek      II                      30
  S19   M     61       Perioral        II                      35
  S20   M     45       Left forearm    II                      35
  S21   M     63       Lower lip       IV                      40
  S22   M     71       Left cheek      IV                      40
  S23   F     73       Right tempus    I                       40
  S24   F     50       Lower lip       III                     40
  S25   F     68       Lower lip       I                       40
  S26   F     30       Right tempus    I                       40
  S27   M     41       Right thigh     I                       40
  S28   F     30       Left eyelid     I                       45
  S29   M     32       Left eyelid     I                       50
  S30   F     20       Nose            I                       50
  S31   F     81       Nose            I                       50
  S32   F     61       Left eyelid     I                       50
  S33   F     60       Left cheek      II                      55
  S34   F     29       Nose            I                       55
  S35   M     86       Right thigh     II--III                 60
  S36   M     82       Nose            III                     60
  S37   F     82       Right cheek     I                       60
  S38   F     75       Right cheek     I                       60
  S39   M     71       Left hand       II                      60
  S40   M     71       Right tempus    I                       60
  S41   F     40       Right hand      I                       70
  S42   M     53       Perioral        I                       70
  S43   F     80       Perioral        I                       70
  S44   M     71       Perioral        I                       70
  S45   M     60       Left eyelid     II                      80
  S46   F     43       Left cheek      I                       80
  S47   F     21       Left cheek      III                     80
  S48   M     79       Lower lip       I                       80
  S49   F     80       Neck            III                     90
  S50   M     90       Nose            II--III                 90
  S51   F     78       Left hand       IV                      95
  S52   M     64       Right cheek     II                      95
  S53   M     57       Neck            I                       100
  S54   F     42       Left hand       I                       100
  S55   M     81       Right hand      I                       100
  S56   M     68       Left eyelid     I                       100
  S57   M     53       Right hand      III                     100
  S58   F     82       Left eyelid     III                     100
  S59   F     71       Upper lip       I                       100
  S60   M     32       Right cheek     I                       110
  S61   F     82       Right cheek     I                       110
  S62   F     75       Right hand      II                      110
  S63   F     74       Upper lip       I                       110
  S64   M     62       Left eyelid     II                      110
  S65   M     47       Nose            II                      110
  S66   M     26       Right hand      III                     120
  S67   F     57       Right hand      I                       120
  S68   F     66       Left tempus     I--II                   130
  S69   M     57       Left thigh      I                       135
  S70   F     81       Left cheek      I                       135
  S71   M     64       Trunk           II                      150
  S72   M     65       Trunk           I                       150
  S73   M     64       Left tempus     I                       160
  S74   M     60       Left eyelid     II                      160
  S75   M     74       Upper lip       II                      160
  S76   F     62       Upper lip       I                       180
  S77   F     66       Right cheek     III                     190

F, female; M, male.

###### 

Demographics and H scores of patients with keratoacanthoma.

  ID    Sex   Age, y   Location       H score
  ----- ----- -------- -------------- ---------
  K01   M     68       Nose           110
  K02   M     55       Left cheek     120
  K03   F     69       Trunk          160
  K04   F     68       Right arm      175
  K05   M     62       Upper lip      180
  K06   F     69       Nose           240
  K07   F     85       Trunk          240
  K08   M     18       Forehead       245
  K09   M     48       Upper lip      245
  K10   F     69       Nose           250
  K11   M     69       Right cheek    250
  K12   M     40       Right arm      250
  K13   F     55       Nose           260
  K14   M     55       Nose           260
  K15   M     50       Left arm       265
  K16   M     50       Upper lip      270
  K17   F     72       Forehead       275
  K18   F     70       Left arm       275
  K19   M     63       Trunk          280
  K20   M     50       Forehead       280
  K21   M     53       Right tempus   280

F, female; M, male.

###### 

Demographics and H scores of negative control patients.

  ID    Sex   Age, y   H score
  ----- ----- -------- ---------
  N01   M     30       220
  N02   F     22       260
  N03   F     57       260
  N04   F     48       275
  N05   M     32       280
  N06   F     50       240
  N07   M     40       280
  N08   M     18       245
  N09   M     39       245
  N10   F     28       250
  N11   F     69       270
  N12   M     55       250

F, female; M, male.

###### 

Distribution of Src homology 3 and multiple ankyrin repeat domains protein-associated RH domain-interacting protein gene mutations in patients with BCC and SCC.

  Tumor type   Exon   Mutation      Modified protein   Frequency   Domain
  ------------ ------ ------------- ------------------ ----------- --------
  BCC          E1     c.10 C\>T     p.Pro4Leu          1/55        --
               --     c.68 C\>T     p.Ala23Val         1/55        --
               --     c.146 A\>G    p.Asp49Gly         1/55        --
               E2     c.329 T\>C    p.Gln110Arg        1/55        PH
               E5     c.733 C\>A    p.His245Thr        1/55        UBL
               E7     c.937 C\>T    p.Pro313Ser        1/55        --
               --     c.944 A\>G    p.His315Arg        1/55        --
               --     c.992 T\>C    p.Leu332Ser        3/55        --
               E8     c.1109 T\>C   p.Met370Thr        1/55        NZF
               --     c.1137 G\>A   p.Trp379Gln        1/55        --
  SCC          E1     c.53 C\>A     p.Ala18Asp         1/47        --
               E2     c.214 T\>C    p.Trp72Arg         1/47        PH
               E3     c.421 C\>T    p.Pro141Ser        1/47        --
               --     c.466 C\>T    p.Pro156Ser        1/47        --
               --     c.469 C\>T    p.Pro157Ser        1/47        --
               --     c.478 G\>A    p.Ala160Thr        1/47        --
               E5     c.709 T\>C    p.Ser237Pro        1/47        --
               E8     c.1007 G\>T   p.Gly336Val        1/47        --

BCC, basal cell carcinoma; SCC, squamous cell carcinoma; PH, pleckstrin homology domain; UBL, ubiquitin-like; NZF, Npl4 zinc finger.
